As of Q4'25 (2025-12-31), Pfizer's diluted EPS stands at -0.29 USD, reflecting a sharp decline from the previous quarter's 0.62 USD. The year-over-year EPS growth rate for this period is -514.29%, indicating a significant deterioration in earnings performance compared to Q4'24. Over the period from Q1'23 to Q4'25, Pfizer's diluted EPS has exhibited considerable volatility, with notable swings between positive and negative values. After reaching a low of -0.59 USD in Q4'23, EPS rebounded to a peak of 0.78 USD in Q3'24 before declining again. The YoY growth rate also fluctuated widely, highlighted by a dramatic 50% surge in Q2'25 and steep declines in several quarters, underscoring ongoing instability in the company's earnings trajectory during this timeframe.